Skip to main content

Table 1 Key aspects that need to be considered for clinical implementation of model-based dosing recommendations

From: Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedure

1Development and implementation of miniaturised bedside analytics in order to minimise pre-analytical variability and facilitate drug monitoring
2External validation of pharmacokinetic models and, if appropriate, further refinement in order to assess the predictive power and decrease the uncertainties of model predictions
3Development of optimised limited sampling strategies to keep the burden of blood sampling for children at a minimum
4Clinical validation of model-based dosing recommendations in a prospectively designed clinical trial